

SEQUENCE LISTING

<110> InflaRx GmbH

<120> TREATMENT OF INFLAMMATORY DISEASES WITH INHIBITORS OF C5A
ACTIVITY

<130> 680-17 PCT

<150> EP 17177657.8

<151> 2017-06-23

<150> EP 17189938.8

<151> 2017-09-07

<160> 34

<170> PatentIn version 3.5

<210> 1

<211> 74

<212> PRT

<213> Homo sapiens

<400> 1

Thr	Leu	Gln	Lys	Lys	Ile	Glu	Glu	Ile	Ala	Ala	Lys	Tyr	Lys	His	Ser
1				5					10					15	

Val	Val	Lys	Lys	Cys	Cys	Tyr	Asp	Gly	Ala	Cys	Val	Asn	Asn	Asp	Glu
			20					25					30		

Thr	Cys	Glu	Gln	Arg	Ala	Ala	Arg	Ile	Ser	Leu	Gly	Pro	Arg	Cys	Ile
		35					40					45			

Lys	Ala	Phe	Thr	Glu	Cys	Cys	Val	Val	Ala	Ser	Gln	Leu	Arg	Ala	Asn
	50					55					60				

Ile	Ser	His	Lys	Asp	Met	Gln	Leu	Gly	Arg
65					70				

<210> 2

<211> 9

<212> PRT

<213> Homo sapiens

<400> 2

Asn Asp Glu Thr Cys Glu Gln Arg Ala
1 5

<210> 3

<211> 7

<212> PRT

<213> Homo sapiens

<400> 3

Ser His Lys Asp Met Gln Leu
1 5

<210> 4

<211> 7

<212> PRT

<213> Homo sapiens

<400> 4

Asp Glu Thr Cys Glu Gln Arg
1 5

<210> 5

<211> 5

<212> PRT

<213> Homo sapiens

<400> 5

His Lys Asp Met Gln
1 5

<210> 6

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> IFX-1 CDR3 heavy chain

<400> 6

Cys Ala Arg Gly Asn Asp Gly Tyr Tyr Gly Phe Ala Tyr

1 5 10

<210> 7
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> INab708 CDR3 heavy chain

<400> 7

Cys	Thr	Arg	Arg	Gly	Leu	Tyr	Asp	Gly	Ser	Ser	Tyr	Phe	Ala	Tyr
1				5				10						15

<210> 8
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> IFX-1 CDR3 light chain

<400> 8

Cys	Gln	Gln	Ser	Asn	Glu	Asp	Pro	Tyr	Thr
1				5				10	

<210> 9
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> INab708 CDR3 light chain

<400> 9

Cys	Gln	Gln	Asn	Asn	Glu	Asp	Pro	Leu	Thr
1				5				10	

<210> 10
<211> 12
<212> PRT
<213> Artificial Sequence

<220>

<223> IFX-1 CDR2 heavy chain

<400> 10

Ile Asp Pro Ser Asp Ser Glu Ser Arg Leu Asp Gln
1 5 10

<210> 11

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> INab708 CDR2 heavy chain

<400> 11

Ile Leu Pro Gly Ser Gly Ser Thr Asn Tyr Asn Glu
1 5 10

<210> 12

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> IFX-1 CDR2 light chain

<400> 12

Ile Tyr Ala Ala Ser Asn Leu
1 5

<210> 13

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> INab708 CDR2 light chain

<400> 13

Ile Tyr Ala Ala Ser Asn Leu
1 5

<210> 14
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> IFX-1 CDR1 heavy chain

<400> 14

Cys Lys Ala Ser Gly Tyr Ser Phe Thr Thr Phe Trp Met Asp
1 5 10

<210> 15
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> INab708 CDR1 heavy chain

<400> 15

Cys Lys Ala Thr Gly Asn Thr Phe Ser Gly Tyr Trp Ile Glu
1 5 10

<210> 16
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> IFX-1 CDR1 light chain

<400> 16

Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp Gly Asp Ser Tyr Met Lys
1 5 10 15

<210> 17
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> INab708 CDR1 light chain

<400> 17

Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp Gly Asp Ser Tyr Met Asn
1 5 10 15

<210> 18

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IFX-1 FR1 heavy chain

<400> 18

Gln Val Gln Leu Gln Gln Ser Gly Pro Gln Leu Val Arg Pro Gly Thr
1 5 10 15

Ser Val Lys Ile Ser
20

<210> 19

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IFX-1 FR2 heavy chain

<400> 19

Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Arg
1 5 10 15

<210> 20

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> IFX-1 FR3 heavy chain

<400> 20

Arg Phe Lys Asp Arg Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr

1	5	10	15
Val	Tyr	Met	Gln
		Leu	Ser
		Ser	Pro
		Thr	Ser
		Glu	Asp
		Ser	Ala
		Val	Tyr
	20	25	30

Tyr

<210> 21
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IFX-1 FR4 heavy chain

<400> 21

Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser
1				5					10	

<210> 22
 <211> 22
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IFX-1 FR1 light chain

<400> 22

Asp	Ile	Val	Leu	Thr	Gln	Ser	Pro	Ala	Ser	Leu	Ala	Val	Ser	Leu	Gly
1				5					10					15	

Gln	Arg	Ala	Thr	Ile	Ser
					20

<210> 23
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IFX-1 FR2 light chain

<400> 23

Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu
1 5 10

<210> 24

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> IFX-1 FR3 light chain

<400> 24

Gln Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp
1 5 10 15

Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr
20 25 30

Tyr

<210> 25

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> IFX-1 FR4 light chain

<400> 25

Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
1 5 10

<210> 26

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> INab708 FR1 heavy chain

<400> 26

Val Gln Leu Leu Glu Ser Gly Ala Glu Leu Met Lys Pro Gly Ala Ser
1 5 10 15

Val Lys Ile Ser
20

<210> 27

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> INab708 FR2 heavy chain

<400> 27

Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile Gly Glu
1 5 10 15

<210> 28

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> INab708 FR3 heavy chain

<400> 28

Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Asn Thr
1 5 10 15

Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr
20 25 30

Tyr

<210> 29

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> INab708 FR4 heavy chain

<400> 29

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala
1 5 10

<210> 30

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> INab708 FR1 light chain

<400> 30

Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
1 5 10 15

Gln Arg Ala Thr Ile Ser
20

<210> 31

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> INab708 FR2 light chain

<400> 31

Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu
1 5 10

<210> 32

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> INab708 FR3 light chain

<400> 32

Gly Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp
1 5 10 15

Phe Thr Leu Asn Ile His Pro Val Glu Glu Val Ala Ala Thr Tyr
20 25 30

Tyr

<210> 33

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> INab708 FR4 light chain

<400> 33

Phe Gly Ala Gly Thr Leu Leu Glu Leu Lys
1 5 10

<210> 34

<211> 40

<212> RNA

<213> Artificial Sequence

<220>

<223> pegylated mixed L-RNA/DNA-aptamer NOX-D21

<220>

<221> misc_feature

<222> (1)..(1)

<223> substituted by 40 kDaPEG-aminohexyl-

<220>

<221> misc_feature

<222> (7)..(7)

<223> desoxy uridine

<220>

<221> misc_feature
<222> (28)..(28)
<223> desoxy uridine

<220>
<221> misc_feature
<222> (38)..(38)
<223> desoxy cytidine

<400> 34
gcgauguggu ggugaagggg uguugggugu cgacgcacgc